Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).

Официальное название

Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP)

Обзор

Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The investigators will perform a United States definitive multicenter phase 3 randomized controlled trial of the low molecular weight heparin enoxaparin as primary venous thromboembolism prophylaxis among critically ill adolescents who are classified a priori as high risk based upon the investigators validated risk prediction models.

Подробное описание

This trial will establish definitive evidence on the comparative efficacy and safety of pharmacological thromboprophylaxis with the low molecular weight heparin (LMWH) enoxaparin versus no pharmacological thromboprophylaxis for the primary prevention of venous thromboembolism (VTE), including deep vein thrombosis and/or pulmonary embolism) among critically ill adolescents who meet a priori criteria for high risk of hospital-acquired (HA-) VTE. In the past two decades, the diagnosis of pediatric hospital-acquired VTE (HA-VTE) in the U.S. has increased 130-200-fold. The investigators have shown that critically-ill adolescents are one the highest risk subpopulations for HA-VTE, with average occurrence rates of 13.2% (range: 6.3-19.8%), and have derived and prospectively validated risk models for HA-VTE in this population. Despite a simultaneously increased risk of bleeding in critically ill adolescents, particularly after surgery or major trauma, an investigator-initiated multicenter phase 2 trial recently led by the investigators group during the COVID-19 pandemic demonstrated the safety of LMWH for primary HA-VTE prevention. To date, risk-stratified phase 3 Randomized Controlled Trials (RCTs) of LMWH thromboprophylaxis as primary HA-VTE prevention in children have not been performed. The investigators will perform a U.S.-based definitive multicenter phase 3 RCT of the LMWH enoxaparin versus no pharmacological thromboprophylaxis for VTE prevention among critically ill adolescents at highest a priori risk for HA-VTE applying evidence from the investigators published risk prediction models.

Вмешательства

• Препарат Enoxaparin
  Enoxaparin thromboprophylaxis administered subcutaneously twice daily (every 12 hours) from enrollment through pediatric intensive care unit discharge

Первичные конечные точки

• Risk (i.e., cumulative incidence) of Symptomatic venous thromboembolism [Срок оценки: From randomization through discharge from the pediatric intensive care unit, approximately 1-2 weeks]
• Risk (i.e., cumulative incidence) of Clinically relevant bleeding [Срок оценки: From randomization through discharge from the pediatric intensive care unit, approximately 1-2 weeks]

Вторичные конечные точки (4)

• Net Clinical Benefit - Modelled Attributable Risk Difference in HA-VTE (Efficacy) by Attributable Risk Difference in clinically relevant bleeding (Safety) [Срок оценки: From randomization through discharge from the pediatric intensive care unit, approximately 1-2 weeks]
• Risk (i.e. cumulative incidence) of symptomatic venous thromboembolism [Срок оценки: From randomization through 30-days post discharge from the pediatric intensive care unit]
• Risk (i.e. cumulative incidence) of clinically relevant bleeding [Срок оценки: From randomization through 30-days post discharge from the pediatric intensive care unit]
• Serious adverse events [Срок оценки: From randomization through 30-days post discharge from the pediatric intensive care unit]

Критерии участия

Критерии включения

• Admission Age between 12- 18 years of age
• Within 24 hours of pediatric intensive care unit (PICU) admission for enrollment
• Presence of a Central Venous Catheter
• Presumed or confirmed infection or systemic inflammatory condition

Критерии исключения

• Active treatment for VTE or known VTE present prior to or on pediatric intensive care unit (PICU) admission
• Current receipt of an antithrombotic agent excluding unfractionated heparin for vascular catheter patency
• Active ISTH-defined clinically relevant bleeding
• Surgery in the last 7-days
• Major trauma within the last 7-days
• Admission for management of congenital heart disease including perioperative management of critical congenital heart disease
• Presence of coagulopathy including:
• International normalized ratio (INR) 2.0 activated partial thromboplastin time (aPTT) 50 seconds Platelet count 50 x103/mL
• Creatinine clearance 30 ml/min/1.73 m2
• Known hypersensitivity to heparin or pork products
• Laboratory confirmed heparin induced thrombocytopenia
• Current pregnancy or lactation,
• Presence of an epidural catheter
• Prior enrollment in the CRITICAL-Teens-TP Trial

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Простое слепое

Основная цель

Профилактика

Центры проведения

США · 1 центр

• Johns Hopkins All Children"s Hospital — St. Petersburg

Публикации

• Sochet AA, Amankwah EK, Andalib V, Jaffray J, Male C, Faustino EV, Goldenberg NA; Pedi-ATLAS Group and the Antithrombotic Trials Working Party of the Pediatric Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Enhanced trial efficiency of the novel "contemporaneous control recapture" parallel-cohort RCT design: Methods and application in the CRITI PMID 41223938

Идентификаторы

NCT: NCT06628778 · IRB00507234-CRITICAL-Teens-TP

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗